Leif W Ellisen

25PUBLICATIONS
101CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Medical virologyPredictive and prognostic markersLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Jun 17, 2026
Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells.

|Apr 02, 2025
Correction: CREB1-BCL2 drives mitochondrial resilience in RAS GAP-dependent breast cancer chemoresistance.

Ki-Fong Man, Omeed Darweesh, Jinghui Hong

|Jan 31, 2025
CREB1-BCL2 drives mitochondrial resilience in RAS GAP-dependent breast cancer chemoresistance.

Ki-Fong Man, Omeed Darweesh, Jinghui Hong

|Jan 08, 2025
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER).

Laura M Spring, Lauren Scarpetti, Arielle J Medford

|Jan 02, 2025
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.

Rachel O Abelman, Bogang Wu, Haley Barnes

|May 07, 2024
Author Correction: Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair.

Yumin Wang, Boya Gao, Luyuan Zhang

Pageof 5

Frequent Collaborators

12 joint publications

Steven J Isakoff

6 joint publications

Dejan Juric

6 joint publications

Laura Spring

6 joint publications

Siang-Boon Koh